Atorvastatin Calcium: An Addition to HMG‐CoA Reductase Inhibitors
- 12 November 1997
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 17 (6) , 1157-1177
- https://doi.org/10.1002/j.1875-9114.1997.tb03081.x
Abstract
No abstract availableThis publication has 60 references indexed in Scilit:
- The Expanding Role of Pharmacy and Therapeutics CommitteesPharmacoEconomics, 1996
- Effects of Atorvastatin, an HMG‐CoA Reductase Inhibitor, on Hepatic Oxidative Metabolism of AntipyrineThe Journal of Clinical Pharmacology, 1996
- Effect of Age and Gender on Pharmacokinetics of Atorvastatin in HumansThe Journal of Clinical Pharmacology, 1996
- Effect of Food on the Bioavailability of Atorvastatin, an HMG‐CoA Reductase InhibitorThe Journal of Clinical Pharmacology, 1995
- SimvastatinDrugs, 1995
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitorsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- The Pathogenesis of Atherosclerosis — An UpdateNew England Journal of Medicine, 1986
- Defective Lipoprotein Receptors and AtherosclerosisNew England Journal of Medicine, 1983